Patients with systemic lupus erythematosus presenting with neuropsychiatric symptoms
Care Setting
Emergency department
Key Highlights
Cerebrospinal fluid antisuprabasin antibody showed greater diagnostic accuracy for NPSLE compared to other tests.
The study included 148 patients with SLE who underwent lumbar puncture.
CSF antisuprabasin antibody had 81% sensitivity and 74% specificity at an optimal cutoff of 76.36 ng/mL.
A combined model of CSF antisuprabasin antibody, CSF white blood cell count, and serum antiribosomal P antibody yielded an area under the curve of 0.892.
The study calls for multicenter longitudinal studies to validate findings.
Guideline-Based Recommendations
Diagnosis
Use cerebrospinal fluid antisuprabasin antibody for identifying NPSLE among SLE patients with neuropsychiatric symptoms.
Management
Monitoring & Follow-up
Risks
Single-center design and limited cohort size may restrict generalizability.
Patient & Prescribing Data
Patients with systemic lupus erythematosus and neuropsychiatric symptoms.
The posttreatment trajectory of CSF antisuprabasin antibody remains unknown.
Clinical Best Practices
Consider CSF antisuprabasin antibody testing in patients with SLE presenting with neuropsychiatric symptoms.
The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.
